500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
RATIONALE: Drugs used in chemotherapy, such as cisplatin, irinotecan, carboplatin, and
etoposide, use different ways to stop tumor cells from dividing so they stop growing or die.
Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with
radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cisplatin and irinotecan followed by
carboplatin, etoposide, and radiation therapy in treating patients who have limited-stage
small cell lung cancer.
Active, not recruiting
Ages:18 and older
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed small cell lung cancer (SCLC) - Limited stage disease, defined as the following: - Disease restricted to 1 hemithorax with regional lymph node metastases, including hilar, ipsilateral, or contralateral mediastinal lymph nodes - No clinically suspected or confirmed supraclavicular lymph node metastases - No pathologically enlarged contralateral hilar lymph nodes - No pleural effusions that are visible on plain chest radiographs, whether they are cytologically positive or negative - Unidimensionally measurable disease - At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan - Pleural/pericardial effusions are not considered measurable PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin less than 1.5 mg/dL - AST less than 2 times upper limit of normal Renal - Creatinine no greater than 2.0 mg/dL Other - Not pregnant or nursing - Fertile patients must use effective contraception - No "currently active" second malignancy except nonmelanoma skin cancer - Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy - No prior chemotherapy for SCLC - No other concurrent chemotherapy Endocrine therapy - No concurrent hormonal therapy except the following: - Steroids for adrenal failure - Hormones administered for non-disease-related conditions (e.g., insulin for diabetes) - Intermittent dexamethasone as an antiemetic or adjunct to prophylactic cranial radiotherapy Radiotherapy - See Endocrine therapy - No prior radiotherapy for SCLC - No concurrent intensity-modulated radiotherapy Surgery - Not specified
Sponsor: Cancer and Leukemia Group B
Phase: Phase 2
Trial ID: NCT00072527
Not Accepting Healthy Volunteers